The 2019 ASCO Annual Meeting, taking place May 31 through June 4 in Chicago, brings together more than 40,000 oncology professionals from around the world to present and discuss the latest research in cancer treatment and patient care.

Explore today's late-breaking abstracts below, and read today’s patient-friendly news roundup on Cancer.Net, ASCO’s patient information website. 

Use of Broader Criteria for Clinical Trial Enrollment Would Double Number of Eligible Patients With Lung Cancer LBA108
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as proposed by ASCO and Friends of Cancer Research in 2017, would nearly double the percentage of patients eligible to enroll in clinical trials – from 52.3% to 98.5%. Learn More

Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients With Advanced Urothelial Cancer LBA4505 
A single arm, phase II clinical trial of 125 patients showed treatment with enfortumab vedotin (EV) – a new agent targeting Nectin-4, a protein found in 97% of urothelial cancers – produced responses in 44% of patients with locally advanced or metastatic forms of urothelial cancer. Learn More

Over 60 Percent of Gynecologic Oncologists Say They Have Experienced Sexual Harassment LBA10502
A recent survey of U.S.-based physician members of the Society of Gynecologic Oncology found that 64% of respondents experienced sexual harassment in training or practice; among women, the rate was 71% and among men it was 51%. Learn More

Colorectal Cancer Patients with Liver Metastases Live Just as Long After Laparoscopic Surgery as Open Surgery  LBA3516
The randomized OSLO-COMET trial found that laparoscopic surgery did not change chances of survival, when compared to open surgery, to remove metastases that had spread to the liver in patients with colorectal cancer. Learn More

Find more information about the 2019 ASCO Annual Meeting.